Print
MailNovember 2004
Approval of JNJ to spin-out GI late stage portfolio and early pipeline
November 2006
Company inception (Turnhout, Belgium)
December 2006
Series A financing round of €61m, post-money valuation €72m
May 2008
Resolor filing at EMEA
October 2009
EU approval for Resolor
December 2009
IPO on Euronext, €98m raised, post-money valuation €258m
January 2010
Resolor introduced in Germany. Favourable tax ruling granted (patent income deduction)
March 2010
Resolor introduced in the UK
May 2010
Initiation of phase III clinical trial with prucalopride in patients with opioid induced constipation
